Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR-Mutated NSCLC Ciara Conduit,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

MET-Mutated NSCLC with Major Response to Crizotinib

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

An Unusual Metastatic Site for Primary Lung Cancer: The Spleen

A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non–Small Cell Lung Cancer Patient Biagio Ricciuti,

Numb Chin Syndrome: An Ominous Sign of Lung Cancer

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Cardiac Dysfunction Caused by Osimertinib

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels Lee M. Krug, MD,

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Vamsidhar Velcheti, MD, Manmeet Ahluwalia, MD

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Aya Fukuizumi, MD Journal of Thoracic Oncology

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

PET/CT Findings for Bone Marrow Carcinosis Because of Lung Adenocarcinoma Keisuke Watanabe, MD, Masaharu Shinkai, MD, PhD, Kenjiro Nagai, MD, Nobuhiro.

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Nicholas W. Choong, MD, Robert S. Hellman, MD

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Metastatic Lung Cancer to the Pancreas

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Successful AZD9291 Therapy Based on Circulating T790M

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

David Garfield, MD Journal of Thoracic Oncology

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Robert Comis, MD, The Passing of a “Lung Man”

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina Ambrosini, MD, PhD, Barbara Melotti, MD, Francesca Sperandi, MD, Andrea Ardizzoni, MD Journal of Thoracic Oncology Volume 11, Issue 8, Pages e99-e101 (August 2016) DOI: 10.1016/j.jtho.2016.04.002 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Low-dose computed tomography (CT) (A and B) and fludeoxyglucose F 18 positron emission tomography/CT fused (C and D) transaxial images of a patient studied before (A and C) and after (B and D) treatment. Multiple focal areas of increased tracer uptake (right and left ilium) without corresponding CT abnormalities show metabolic normalization after treatment and appearance of focal hyperdense lesions on the corresponding CT images. Journal of Thoracic Oncology 2016 11, e99-e101DOI: (10.1016/j.jtho.2016.04.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Low-dose computed tomography (CT) (A and B) and fludeoxyglucose F 18 positron emission tomography/CT fused (C and D) transaxial images of a patient studied before (A and C) and after (B and D) treatment. A focal area of increased tracer uptake at the lumbar level without corresponding CT abnormalities shows metabolic normalization after treatment and appearance of focal hyperdense lesions on the corresponding CT images. Journal of Thoracic Oncology 2016 11, e99-e101DOI: (10.1016/j.jtho.2016.04.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Low-dose computed tomography (CT) (A and B) and fludeoxyglucose F 18 positron emission tomography/CT fused (C and D) transaxial images of a patient studied before (A and C) and after (B and D) treatment. An hypermetabolic area at the L3 level showed metabolic normalization at positron emission tomography/CT after treatment, whereas CT revealed an increase in lesion dimensions. Journal of Thoracic Oncology 2016 11, e99-e101DOI: (10.1016/j.jtho.2016.04.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions